AGP
KYMR icon

Artia Global Partners’s Kymera Therapeutics KYMR Stock Holding History

Artia Global Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$749K – 37
2022
Q4 		$749K Buy
+30,000
New +$800K 0.29% 25

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Artia Global Partners's KYMR Position: Q1 2023 in Review

Artia Global Partners sold out of Kymera Therapeutics (KYMR) in Q1 2023, closing a stake of 30,000 shares — an estimated $749K sold.

Artia Global Partners first reported a position in KYMR in Q4 2022 and held it in 1 quarter. The position peaked at $749K in Q4 2022. 127 funds tracked by Wall St. Rank hold KYMR as of Q1 2023.

  • Artia Global Partners reported no remaining Kymera Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Artia Global Partners sold 30,000 Kymera Therapeutics shares in Q1 2023, an estimated $749K.
  • Artia Global Partners first reported a position in Kymera Therapeutics in Q4 2022 and held it in 1 quarter.
  • Artia Global Partners's Kymera Therapeutics position peaked at $749K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2023.

Based on Artia Global Partners's 13F filing for Q1 2023, filed 15 May 2023.